In vivo AAV based gene therapy reduces cardiac conduction defects in TMEM43 mediated arrhythmogenic cardiomyopathy - Lalaguna, L; Lopez-Olaneta, M; Villalba-Orero, M; Garcia-Pavia, P; Lara-Pezzi, E (Human Gene Therapy, 2024)